molt 16 Search Results


dsmz germany  (DSMZ)
94
DSMZ dsmz germany
Dsmz Germany, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dsmz germany/product/DSMZ
Average 94 stars, based on 1 article reviews
dsmz germany - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
molt-16  (CEM Corporation)
90
CEM Corporation molt-16
Growth inhibitory effect of PIK-75 on T-cell acute lymphoblastic leukemia cell lines. (A) Western blot showing the expression of phosphorylated AKT and <t>TAL1</t> in T-cell acute lymphoblastic leukemia (T-ALL) cell lines. (B and C) T-ALL cell lines were treated with PIK-75. Cell viability was measured after 24 hours by CellTiter-Glo. The values shown are the mean ± standard deviation of technical triplicates and are normalized to untreated cells. Cell lines with viability greater than 20% after treatment with 1 mM PIK-75 were considered to be insensitive. Not able to be determined (N.D.), half maximal inhibitory concentration (IC 50 ) values could not be determined by the dose response inhibition function using variable slope by GraphPad Prism. Cell lines grouped based on sensitivity to PIK-75 (B) or TAL1 and AKT status (C). (D) Cell lines ranked according to IC 50 value. TAL1 and AKT status are annotated by color. (E) Jurkat cells were seeded at 10,000 cells per well, treated with dimethyl sulfoxide (DMSO) or PIK-75 (120 nM) for 4 hours and stained with Annexin V-APC and PI. The values shown are the proportions of the total population ± standard deviation of technical triplicates. Representative results from multiple independent experiments were shown (B to E).
Molt 16, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/molt-16/product/CEM Corporation
Average 90 stars, based on 1 article reviews
molt-16 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
molt 16 cells  (Hayashibara Biochemical Laboratories)
90
Hayashibara Biochemical Laboratories molt 16 cells
Growth inhibitory effect of PIK-75 on T-cell acute lymphoblastic leukemia cell lines. (A) Western blot showing the expression of phosphorylated AKT and <t>TAL1</t> in T-cell acute lymphoblastic leukemia (T-ALL) cell lines. (B and C) T-ALL cell lines were treated with PIK-75. Cell viability was measured after 24 hours by CellTiter-Glo. The values shown are the mean ± standard deviation of technical triplicates and are normalized to untreated cells. Cell lines with viability greater than 20% after treatment with 1 mM PIK-75 were considered to be insensitive. Not able to be determined (N.D.), half maximal inhibitory concentration (IC 50 ) values could not be determined by the dose response inhibition function using variable slope by GraphPad Prism. Cell lines grouped based on sensitivity to PIK-75 (B) or TAL1 and AKT status (C). (D) Cell lines ranked according to IC 50 value. TAL1 and AKT status are annotated by color. (E) Jurkat cells were seeded at 10,000 cells per well, treated with dimethyl sulfoxide (DMSO) or PIK-75 (120 nM) for 4 hours and stained with Annexin V-APC and PI. The values shown are the proportions of the total population ± standard deviation of technical triplicates. Representative results from multiple independent experiments were shown (B to E).
Molt 16 Cells, supplied by Hayashibara Biochemical Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/molt 16 cells/product/Hayashibara Biochemical Laboratories
Average 90 stars, based on 1 article reviews
molt 16 cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Growth inhibitory effect of PIK-75 on T-cell acute lymphoblastic leukemia cell lines. (A) Western blot showing the expression of phosphorylated AKT and TAL1 in T-cell acute lymphoblastic leukemia (T-ALL) cell lines. (B and C) T-ALL cell lines were treated with PIK-75. Cell viability was measured after 24 hours by CellTiter-Glo. The values shown are the mean ± standard deviation of technical triplicates and are normalized to untreated cells. Cell lines with viability greater than 20% after treatment with 1 mM PIK-75 were considered to be insensitive. Not able to be determined (N.D.), half maximal inhibitory concentration (IC 50 ) values could not be determined by the dose response inhibition function using variable slope by GraphPad Prism. Cell lines grouped based on sensitivity to PIK-75 (B) or TAL1 and AKT status (C). (D) Cell lines ranked according to IC 50 value. TAL1 and AKT status are annotated by color. (E) Jurkat cells were seeded at 10,000 cells per well, treated with dimethyl sulfoxide (DMSO) or PIK-75 (120 nM) for 4 hours and stained with Annexin V-APC and PI. The values shown are the proportions of the total population ± standard deviation of technical triplicates. Representative results from multiple independent experiments were shown (B to E).

Journal: Haematologica

Article Title: Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in T-cell acute lymphoblastic leukemia

doi: 10.3324/haematol.2022.280761

Figure Lengend Snippet: Growth inhibitory effect of PIK-75 on T-cell acute lymphoblastic leukemia cell lines. (A) Western blot showing the expression of phosphorylated AKT and TAL1 in T-cell acute lymphoblastic leukemia (T-ALL) cell lines. (B and C) T-ALL cell lines were treated with PIK-75. Cell viability was measured after 24 hours by CellTiter-Glo. The values shown are the mean ± standard deviation of technical triplicates and are normalized to untreated cells. Cell lines with viability greater than 20% after treatment with 1 mM PIK-75 were considered to be insensitive. Not able to be determined (N.D.), half maximal inhibitory concentration (IC 50 ) values could not be determined by the dose response inhibition function using variable slope by GraphPad Prism. Cell lines grouped based on sensitivity to PIK-75 (B) or TAL1 and AKT status (C). (D) Cell lines ranked according to IC 50 value. TAL1 and AKT status are annotated by color. (E) Jurkat cells were seeded at 10,000 cells per well, treated with dimethyl sulfoxide (DMSO) or PIK-75 (120 nM) for 4 hours and stained with Annexin V-APC and PI. The values shown are the proportions of the total population ± standard deviation of technical triplicates. Representative results from multiple independent experiments were shown (B to E).

Article Snippet: In particular, five TAL1-positive cell lines that exhibited constitutive AKT phosphorylation on Ser473 (MOLT-16, MOLT-4, Jurkat, CCRF-CEM, RPMI-8402) were more sensitive than those that exhibited constitutive AKT phosphorylation but did not express TAL1 (SUP-T1, HPB-ALL, LOUCY, P12-ICHIKAWA) ( and ).

Techniques: Western Blot, Expressing, Standard Deviation, Concentration Assay, Inhibition, Staining

Gene expression changes afer PIK-75 treatment in T-cell acute lymphoblastic leukemia cells. (A and B) mRNA expression levels of GIMAP cluster genes (A) and other TAL1 targets (B) in Jurkat cells 4 hours after PIK-75 treatment (120 nM). Expression values were normalized to spike-in RNA and shown as individual dots and mean ± standard deviation of biological duplicates and technical duplicates. Representative results from multiple independent experiments were shown. (C) MA plot showing the average of normalized counts vs . log 2 -normalized fold change (FC) between samples treated with dimethyl sulfoxide (DMSO) and PIK-75, estimated using DESeq2 with or without spike-in normalization. Each individual gene and spike-in control are represented by a single dot. RefSeq genes that showed statistically significant differences (adjusted P value <0.01) are colored blue. Similarly, spike-in controls are shown in purple (adjusted P value <0.01) or orange. N.S.: not significant.

Journal: Haematologica

Article Title: Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in T-cell acute lymphoblastic leukemia

doi: 10.3324/haematol.2022.280761

Figure Lengend Snippet: Gene expression changes afer PIK-75 treatment in T-cell acute lymphoblastic leukemia cells. (A and B) mRNA expression levels of GIMAP cluster genes (A) and other TAL1 targets (B) in Jurkat cells 4 hours after PIK-75 treatment (120 nM). Expression values were normalized to spike-in RNA and shown as individual dots and mean ± standard deviation of biological duplicates and technical duplicates. Representative results from multiple independent experiments were shown. (C) MA plot showing the average of normalized counts vs . log 2 -normalized fold change (FC) between samples treated with dimethyl sulfoxide (DMSO) and PIK-75, estimated using DESeq2 with or without spike-in normalization. Each individual gene and spike-in control are represented by a single dot. RefSeq genes that showed statistically significant differences (adjusted P value <0.01) are colored blue. Similarly, spike-in controls are shown in purple (adjusted P value <0.01) or orange. N.S.: not significant.

Article Snippet: In particular, five TAL1-positive cell lines that exhibited constitutive AKT phosphorylation on Ser473 (MOLT-16, MOLT-4, Jurkat, CCRF-CEM, RPMI-8402) were more sensitive than those that exhibited constitutive AKT phosphorylation but did not express TAL1 (SUP-T1, HPB-ALL, LOUCY, P12-ICHIKAWA) ( and ).

Techniques: Gene Expression, Expressing, Standard Deviation, Control

The effect of PIK-75 on TAL1 targets and super-enhancer-associated genes. (A) Gene set enrichment analysis (GSEA) to determine overall correlation between the change in gene expression after PIK-75 treatment in Jurkat cells and specific set of genes. The list of high-confidence TAL1 target genes (bound by TAL1 and downregulated after TA L 1 knockdown in Jurkat cells) and of super-enhancer associated genes were used as gene sets. (B) Heatmap showing the expression of TAL1 targets after PIK-75 treatment. (C) Gene ontology analysis was performed using genes that were significantly downregulated (base mean >10, log 2 (fold change) × -log 10 ( P value) <-1, adjusted P value <0.01) in Jurkat cells 4 hours after PIK-75 treatment. The top 10 terms were selected according to the adjusted P value and are shown according to the combined score. Adjusted P value was calculated using Fisher’s exact test.

Journal: Haematologica

Article Title: Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in T-cell acute lymphoblastic leukemia

doi: 10.3324/haematol.2022.280761

Figure Lengend Snippet: The effect of PIK-75 on TAL1 targets and super-enhancer-associated genes. (A) Gene set enrichment analysis (GSEA) to determine overall correlation between the change in gene expression after PIK-75 treatment in Jurkat cells and specific set of genes. The list of high-confidence TAL1 target genes (bound by TAL1 and downregulated after TA L 1 knockdown in Jurkat cells) and of super-enhancer associated genes were used as gene sets. (B) Heatmap showing the expression of TAL1 targets after PIK-75 treatment. (C) Gene ontology analysis was performed using genes that were significantly downregulated (base mean >10, log 2 (fold change) × -log 10 ( P value) <-1, adjusted P value <0.01) in Jurkat cells 4 hours after PIK-75 treatment. The top 10 terms were selected according to the adjusted P value and are shown according to the combined score. Adjusted P value was calculated using Fisher’s exact test.

Article Snippet: In particular, five TAL1-positive cell lines that exhibited constitutive AKT phosphorylation on Ser473 (MOLT-16, MOLT-4, Jurkat, CCRF-CEM, RPMI-8402) were more sensitive than those that exhibited constitutive AKT phosphorylation but did not express TAL1 (SUP-T1, HPB-ALL, LOUCY, P12-ICHIKAWA) ( and ).

Techniques: Gene Expression, Knockdown, Expressing